Nuvessa

Pouchitis, Liver Abscess, Amebic, Lung Abscess + 53 more

Treatment

41 FDA approvals

20 Active Studies for Nuvessa

What is Nuvessa

Metronidazole

The Generic name of this drug

Treatment Summary

Metronidazole is an antibiotic used to treat a variety of bacterial and parasitic infections. It is most commonly used to treat infections of the gastrointestinal tract, trichomoniasis, giardiasis, and amebiasis. Metronidazole is available in several forms including capsules, tablets, topical applications, and suppositories. It has been used as an antibiotic for many years and is known for its broad range of uses.

Flagyl

is the brand name

Nuvessa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Flagyl

Metronidazole

1963

449

Approved as Treatment by the FDA

Metronidazole, commonly known as Flagyl, is approved by the FDA for 41 uses including Bone and Joint Infections and Abscess .

Bone and Joint Infections

Abscess

Liver Abscess

Communicable Diseases

Bacterial Endocarditis

Osteomyelitis

Helicobacter Pylori Infection

Used to treat Helicobacter Pylori Infection in combination with Bismuth subsalicylate

Abdominal Abscess

Abdominal Infection

Skin and skin structure infections

Gynaecological infection

Lung Abscess

Endometritis

Central Nervous System Bacterial Infections

Bacterial Meningitis

Pneumonia

intra-abdominal bacterial infections

hepatic abscess

Tubo-ovarian abscess

Lung Abscess

Curling Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Lower respiratory tract infection bacterial

Bacterial Septicemia

Bacteria, Anaerobic

Bacterial Infections

Duodenal Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Meningitis

Abscess, Intra-Abdominal

Empyema

asymptomatic Trichomoniasis

Exposure via partner

Endomyometritis

Bacterial Peritonitis

Central Nervous System Bacterial Infections

Empyema

Trichomonas Infections

Endometritis

Endometritis

Bacteria

Endocarditis, Bacterial

Communicable Diseases

Effectiveness

How Nuvessa Affects Patients

Metronidazole is a medication used to treat amebiasis, trichomoniasis, and giardiasis. It has antibacterial and antiprotozoal properties and is effective against certain anaerobic bacteria. However, it does not work against most other types of bacteria or fungi. Metronidazole can cause nerve damage, convulsions, and numbness, especially when taken in high doses. It has also been found to be carcinogenic in mice and rats, though the effect on humans is unclear. It is important to only take metronidazole when necessary and only for its approved indications.

How Nuvessa works in the body

Metronidazole is used to target anaerobic bacteria and protozoa. It does this by entering the cells of these organisms and blocking their ability to make DNA. Metronidazole is reduced in the cells, producing toxic metabolites that damage the DNA and make it difficult for the organisms to replicate.

When to interrupt dosage

The measure of Nuvessa is dependent upon the specified condition, including Exposure via partner, Skin and Curling Ulcer. The degree of dosage is indicated in the table beneath, contingent upon the approach of delivery (e.g. Capsule or Vaginal).

Condition

Dosage

Administration

Uterine Cervicitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Bacterial Vaginosis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Vulvovaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Tubo-ovarian abscess

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Exposure via partner

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Communicable Diseases

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Trichomonas Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Candida albicans

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Bacterial Peritonitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

post-surgical vaginal cuff infection

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Giardiasis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Inflammatory Papule

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Pouchitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Bacterial Septicemia

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Bacterial Meningitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Sinusitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Endocarditis, Bacterial

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Operative Surgical Procedures

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Lockjaw

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Cream, Cream - Topical, Tablet - Oral, Vaginal, Gel - Vaginal, Lotion, Lotion - Topical, Solution - Intravenous, Oral, Tablet, Capsule, Capsule - Oral, Kit, Suppository, Cream - Vaginal, Suppository - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, Tablet, film coated - Oral, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release - Oral, Ointment, Ointment - Topical, Solution, Tablet, film coated, extended release, Injection - Intravenous, Kit - Oral, Insert - Vaginal, Insert

Warnings

Nuvessa Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

Pregnancy Trimester, First

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

There are 20 known major drug interactions with Nuvessa.

Common Nuvessa Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Metronidazole.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Metronidazole.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Metronidazole.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Metronidazole.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Metronidazole.

Nuvessa Toxicity & Overdose Risk

The maximum toxic dose of metronidazole in rats is 5000mg/kg. Symptoms of an overdose include nerve damage, poisoning of the central nervous system, seizures, feeling sick after drinking alcohol, dark urine, a metallic taste in the mouth, nausea, stomach discomfort, dizziness, and low white blood cell count. There is no specific treatment for an overdose and treatment should involve providing supportive care and giving activated charcoal to help remove the unabsorbed drug from the digestive system. Contact the local poison control center for more information on how to manage a metronidazole overdose.

Nuvessa Novel Uses: Which Conditions Have a Clinical Trial Featuring Nuvessa?

179 active studies are being conducted to evaluate the potential of Nuvessa in treating Curling Ulcer, Periodontitis and Central Nervous System Bacterial Infections.

Condition

Clinical Trials

Trial Phases

Lockjaw

0 Actively Recruiting

Uterine Cervical Erosion

0 Actively Recruiting

Gum Disease

3 Actively Recruiting

Phase 3, Not Applicable

Abdominal Infection

0 Actively Recruiting

Rosacea

0 Actively Recruiting

Balantidiasis

0 Actively Recruiting

Empyema

1 Actively Recruiting

Phase 4

Abdominal Abscess

2 Actively Recruiting

Phase 4, Phase 1, Phase 2

Bacteria

0 Actively Recruiting

Trichomonas Infections

0 Actively Recruiting

Vulvovaginitis

0 Actively Recruiting

Lung Abscess

0 Actively Recruiting

Pouchitis

5 Actively Recruiting

Phase 2, Phase 3, Early Phase 1, Phase 4

Atopic Dermatitis

9 Actively Recruiting

Phase 2, Phase 3, Phase 4

Acne Vulgaris

0 Actively Recruiting

Operative Surgical Procedures

0 Actively Recruiting

Liver Abscess, Amebic

0 Actively Recruiting

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Amebic colitis

0 Actively Recruiting

Rosacea

2 Actively Recruiting

Early Phase 1, Phase 2

Nuvessa Reviews: What are patients saying about Nuvessa?

3

Patient Review

3/16/2020

Nuvessa for Vaginosis caused by Bacteria

I had been struggling with BV for over a year when I was finally prescribed Nuvaessa. It worked great at first, and kept the infection away for three months! However, my body seems to have built up a tolerance to the medication because it now comes back much sooner after taking Nuvaessa.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nuvessa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Nuvessa used for?

"NUVESSA® is a prescription medicine that is used to treat bacterial vaginal infections in females who are at least 12 years old. The safety and effectiveness of NUVESSA® in female children who are younger than 12 years old has not been determined."

Answered by AI

Is Nuvessa the same as metronidazole?

"NUVESSA is an aqueous gel that contains 1.3% metronidazole. The gel is formulated to have a pH of 4.0. The gel also contains benzyl alcohol, methylparaben, polycarbophil, polyethylene glycol 400, propylene glycol, propylparaben, and purified water."

Answered by AI

How effective is Nuvessa?

"The rest of the reviewers reported no change.

Nuvessa has an average rating of 6.8 from 8 reviews for the treatment of Bacterial Vaginosis. 25% of reviewers said it was effective, while 13% said it was not effective. The rest of the reviewers reported no change."

Answered by AI

How often can I use Nuvessa?

"Nuvessa may be used as a single dose, or for up to 5 nights in a row as needed."

Answered by AI

Clinical Trials for Nuvessa

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Nuvessa clinical trials?

We made a collection of clinical trials featuring Nuvessa, we think they might fit your search criteria.
Go to Trials
Image of UNC Chapel Hill in Chapel Hill, United States.

Intrapleural Enzyme Therapy for Pleural Infection

18+
All Sexes
Chapel Hill, NC

The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed through a chest tube into the space between the lung and the chest wall to help clear out the infection. The investigators are trying to learn: * Does using the medicine once a day work just as well as using it twice a day? * Are there any differences in outcomes between patients who get the medicine once a day versus twice a day? * Does more or less fluid remain in the chest (seen on a chest x-ray) depending on how often the medicine is given? Participants will: * Have an infection around their lung and will already be getting normal hospital care, including a chest tube to drain the infected fluid around their lung. * Be asked to give permission to join the study. * Be randomly chosen (like flipping a coin) to get the medications either once a day or twice a day through the chest tube.

Phase 4
Waitlist Available

UNC Chapel Hill

Jason Akulian, MD, MPH

Have you considered Nuvessa clinical trials?

We made a collection of clinical trials featuring Nuvessa, we think they might fit your search criteria.
Go to Trials
Image of Office of Dental Health, Department of Health and Senior Services in Jefferson City, United States.

Dental Care for Pneumonia Prevention

60 - 100
All Sexes
Jefferson City, MO

The goal of this study is to learn if dental infection control treatment delivered to older adult nursing home residents at their place of residence will result in : * improved dental health * reduced risk of pneumonia * better glucose control for diabetic patients compared to the pre-project dental and general health evaluations of residents and the pre-project facility incidence of pneumonia. Dental infection control treatment includes treating gum infections, stopping or slowing decay with fluoride, and assisting residents with effective tooth brushing and denture cleaning daily. Previous studies indicate dental infections can be inhaled and cause pneumonia or make diabetes worse. A shortage of dentists has limited care for nursing home residents. This project will allow dental hygienists and specially trained dental assistants to treat nursing home residents using telehealth methods (computers, cameras, internet, and telephone) to talk and work with dentists in different locations.

Recruiting
Has No Placebo

Office of Dental Health, Department of Health and Senior Services

Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA

Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.

Recruiting
Has No Placebo

Benioff Children's Hospital - Oakland (+2 Sites)

Derek J Williams, MD, MPH

Have you considered Nuvessa clinical trials?

We made a collection of clinical trials featuring Nuvessa, we think they might fit your search criteria.
Go to Trials